Radionuclide therapy of neural crest tumors

Abstract

The potential concentration of I 131-Meta-iodo-benzylguanidine (MIBG) in pheochromocytoma, and the successful application in diagnosis and therapy of pheochromocytoma, has led to its use in therapy in other tumours derived from the neural crest. In neuroblastoma, the concentration of MIBG is as reliable as it is in pheochromocytoma. 18 patients with a neuroblastoma were treated, leading to two complete remissions, seven partial remissions, two no change, and two progressive disease; one patient was lost for follow-up. Six adults were treated, three with a carcinoid, two malignant pheochromocytoma and one medullary thyroid carcinoma. Although follow-up is still short, preliminary results of therapeutic use of I 131-MIBG indicate that this treatment modality may be effective.

Metaiodobenzylguanidine assessment of metastatic neuroblastoma: Observer dependency and chemosensitivity evaluation

“…The other bias of these studies is the dose of MIBG used and the duration and timing of the procedure. The more one gives, the more one sees, as is evident when scanning patients after a therapeutic dose [17]. One must thus realize that visible skeletal deposits might just reflect the "tip of the iceberg" and that technical aspects of MIBG scaning should be standardized internationally.…”

Draft guidelines regarding appropriate use of 131I-MIBG radiotherapy for neuroendocrine tumors

“…Malignant pheochromocytoma [2,[5][6][7][8][9][10][11][12][13][14][15][16][17][18] Thyroid medullary carcinoma [5,11,13,[16][17][18][19] Carcinoid tumors [5,11,13,[16][17][18]20] Neuroblastoma [5,[16][17][18][21][22][23][24][25] b. 131 I-MIBG dose…”

Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy

“…As in other advanced/progressive/metastatic NENs, radionuclide therapy may represent a therapeutic option, and indeed, it has been applied in MTC since the 1980s. Historically, the first radiopharmaceutical used in therapy was 131Iodine (131I)-metaiodobenzylguanidine (MIBG) [5,6], but its use has been limited in MTC, due to the low percentage of MTC that shows uptake on MIBG scintigraphy [7][8][9].…”